

08 March 2023

Ticker: AGMR CN Pro-forma cash: C\$26m Project: Reliquias / Dorita

Market cap: C\$51m Price: C\$0.235/sh Country: Peru

REC. (unc): BUY TARGET (unc): C\$0.90/sh RISK RATING (unc): VENTURE

Recall last year's resource validation drilling saw a data cut-off as at the end of November 2022 for maiden 43-101 MRE due imminently. Moreover, with ~17km of drilling, mapping and sampling programs now complete, we're looking for an initial SCPe ~10Moz AgEq in M&I to be earmarked for quick turn-around to mine inventory ahead of the mine restart next year. The significance of today's drilling simply talks to growth beyond this, to be incorporated in a subsequent MRE for the mid-year PEA. Digging in, the averages of all hits saw 1.3m @ 384g/t AgEq, but also 0.5-0.8m @ 1-2kg/t high-grade extensional veins—a great reminder of the potential 'jewel box' opportunities throughout the mine. Even more impressive was the >3:1 hit rate that continued to outline plenty of targets to follow up (incl. step-outs >200m NW of previously reported).

Big picture, with the stock trading at US\$0.26/oz today vs more advanced peers between US\$3-5/oz in situ, the attraction in the short-term is the re-rate potential on low cost restart for potential 2-3Moz AgEq pa from initial 1,000tpd in 2H24, with growth opportunities thereafter on 'hub and spoke' district never before consolidated. As such, we maintain our BUY rating and C\$0.90/sh PT based on conservative US\$2.00/oz AgEq at Reliquias and nominal US\$0.50/oz AgEq at Caudalosa based on combined historical 81Moz @ 838g/t AgEq resource. Upcoming catalysts include the maiden 43-101 in the coming weeks, twin tracked drilling and plant refurb ahead of the official mine restart next year.

AGMR Money properties

Perseguida Vein

Long Section - view to Northeast

SMR 000-22 MTC

Internal 3.50 million 130.5 million 13

Figure 1. Reliquias (A) plan map and (B) long-section showing today's drill hits

Source: Silver Mountain

# Final 2022 assays signal growth opportunities outside of upcoming MRE; 0.8m @ 2.4kg/t AgEq

Silver Mountain reports seven diamond drill holes from their 71-hole (16,955m) 2022 UG drill program at Reliquias highlighted by **0.8m @ 2.4kg/t AgEq** and **0.6m @ 1.7kg/t AgEq** from Perseguida, and **0.6m @ 304g/t AgEq** from the Pozo Rico vein system 120-180m SW of Sacasipudes all at spot. Rehab of 390mL north of Pozo Rico is currently under way ahead of detailed mapping and channel sampling this year. Additional rehab to east of Reliquias is ongoing ahead of drill testing on Pasteur, Vulcano, and Escondida veins below and laterally of historic mine workings.

Separately, on February 14<sup>th</sup>, Silver Mountain reported results from underground channel sampling on the 480 level along the **Meteysaca Vein.** Highlights include **0.9m @ 1,216g/t** AgEq, **0.9m @ 1,152g/t** AgEq, **1.9m @ 705g/t** AgEq, and **0.6m @ 1,361g/t AgEq** (all at spot). Sampling programs have now been completed on 415L and 480L with results to be incorporated into upcoming 43-101 resource. Rehab of 520L is ongoing ahead of next months detailed sampling and mapping program. Additionally, initial mine development work is slated for 3Q23.

Figure 2. Isometric view of the Meteysaca Vein highlighting mapping and channel sampling locations

Source: Silver Mountain

# Why we like Silver Mountain

- Historic 81Moz @ 838g/t AgEq resource (40% M&I) across two adjacent mines in Peru
- Fully permitted for low-cost (SCPe US\$20-30m) initial restart for SCPe 2-3Moz AgEq pa
- Long term SCPe 5-10Moz AgEq pa 'hub and spoke' potential
- Experienced management & board with deep roots in country
- Critically low valuation relative to peers ahead of major catalysts

## **Catalysts**

- 2023: Ongoing underground drilling
- 1Q23: maiden 43-101 resource
- Mid-2023: PEA / MRE update
- 1H24: plant refurbishment completion & restart decision

## Research

**Brandon Gaspar** (Toronto) M: +1 437 533 3142 <u>bgaspar@sprott.com</u> **Eleanor Magdzinski** (Toronto) M: +1 705 669 7456 <u>emagdzinski@sprott.com</u> **Konstantinos Kormpis** (Toronto) M: +1 778-957-3623 <u>kkormpis@sprott.com</u>



Ticker: AGMR CN Author: B. Gaspar / E. Magdzinski	Price/mk Rec / 1xl\		C\$0.235/9 BUY, C\$0.	sh, C\$51m 9/sh		Group P/NAV today:	0.29x		Asset: Country:	Reliquias <i>i</i> Peru	/ Dorita
Non 43-101 resources	Tonnes	*A	gEq	M&I (%)	Ag (%)	Commodity	Price	Recov.	Payab.	NSR*	% totl.
Reliquias	1.5Mt	627g/t	30Moz	46%	50%	Silver (Ag)	24	88%	95%	84%	55%
Caudalosa	1.5Mt	908g/t	45Moz	0%	49%	Copper (Cu)	3.63	54%	95%	51%	21%
Total M&I + Inf resource	3.0Mt	771g/t	75Moz	40%	50%	Zinc (Zn)	1.18	80%	85%	68%	15%
*AgEq calcs using US\$16/oz Ag, US\$1.20/lb Zn, US\$0.95/lb Pb, and US\$2.81/lb Cu						Lead (Pb)	0.90	83%	88%	73%	10%
SOTP <i>project</i> valuation*						Gold (Au)	1850	0%	0%	0%	0%
		C\$m	0/ship	NAVx	C\$/sh	*SCPe Payable recoveral	ble / in-situ, *	Gold not his	torically ass	sayed	
Reliquias NAV @ US\$2.00/oz AgEq		79	100%	1.0x	0.40	Share data	Basic	FD			
Caudalosa NAV @ US\$0.50/oz AgEq		30	100%	1.0x	0.15	Shares (m)	217.5	267.8			
SCPe pro-forma cash		25.5	-	1.0x	0.13						
Cash from options+warrants		29.1	-	1.0x	0.15						
SCPe Group 1xNAV		164		PT:	0.82						
*Ex G&A and fin. costs			Mark	et P/NAV:	0.29x						

Source: SCP estimates

# **Equity Research**

#### **DISCLOSURES & DISCLAIMERS**

This research report (as defined under IIROC Rule 3600, Part B) is issued and approved for distribution in Canada by Sprott Capital Partners LP ("SCP"), an investment dealer who is a member of the Investment Industry Regulatory Organization of Canada ("IROC") and the Canadian Investor Protection Fund ("CIPF"). The general partner of SCP is Sprott Capital Partners GP Inc. and SCP is a wholly-owned subsidiary of Sprott Inc., which is a publicly listed company on the Toronto Stock Exchange under the symbol "SII". Sprott Asset Management LP ("SAM"), a registered investment manager to the Sprott Funds and is an affiliate of SCP. This research report is provided to retail clients and institutional investors for information purposes only. The opinions expressed in this report are the opinions of the author and readers should not assume they reflect the opinions or recommendations of SCP's research department. The information in this report is drawn from sources believed to be reliable but the accuracy or completeness of the information is not guaranteed, nor in providing it does SCP and/or affiliated companies or persons assume any responsibility or liability whatsoever. This report is not to be construed as an offer to sell or a solicitation of an offer to buy any securities. SCP accepts no liability whatsoever for any loss arising from any use or reliance on this research report or the information contained herein. Past performance is not a guarantee of future results, and no representation or warranty, expressed or implied, is made regarding future performance of any security mentioned in this research report. The price of the securities mentioned in this research report and the income they generate may fluctuate and/or be adversely affected by market factors or exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. Furthermore, the securities discussed in this research report may not be liquid investments, may have a high level of volatility or may be subject to additional and special risks associated with securities and investments in emerging markets and/or foreign countries that may give rise to substantial risk and are not suitable for all investors. SCP may participate in an underwriting of, have a position in, or make a market in, the securities mentioned herein, including options, futures or other derivatives instruments thereon, and may, as a principal or agent, buy or sell such products.

### **DISSEMINATION OF RESEARCH:**

SCP's research is distributed electronically through email or available in hard copy upon request. Research is disseminated concurrently to a predetermined list of clients provided by SCP's Institutional Sales Representative and retail Investment Advisors. Should you wish to no longer receive electronic communications from us, please contact <a href="mailto:unsubscribe@sprott.com">unsubscribe@sprott.com</a> and indicate in the subject line your full name and/or corporate entity name and that you wish to unsubscribe from receiving research.

#### RESEARCH ANALYST CERTIFICATION:

Each Research Analyst and/or Associate who is involved in the preparation of this research report hereby certifies that:

- The views and recommendations expressed herein accurately reflect his/her personal views about any and all of the securities or issuers that are the subject matter of this research report;
- His/her compensation is not and will not be directly related to the specific recommendations or view expressed by the Research analyst in this research report;
- They have not affected a trade in a security of any class of the issuer within the 30-day period prior to the publication of this research report;
- They have not distributed or discussed this Research Report to/with the issuer, investment banking group or any other third party
  except for the sole purpose of verifying factual information; and
- They are unaware of any other potential conflicts of interest.

## UK RESIDENTS:

Sprott Partners UK Limited ("Sprott") is an appointed representative of PillarFour Securities LLP which is authorized and regulated by the Financial Conduct Authority. This document has been approved under section 21(1) of the FMSA 2000 by PillarFour Securities LLP ("PillarFour") for communication only to eligible counterparties and professional clients as those terms are defined by the rules of the Financial Conduct Authority. Its contents are not directed at UK retail clients. PillarFour does not provide investment services to retail clients. PillarFour publishes this document as non-independent research which is a marketing communication under the Conduct of Business rules. It has not been prepared in accordance with the regulatory rules relating to independent research, nor is it subject to the prohibition on dealing ahead of the dissemination of investment research. It does not constitute a personal recommendation and does not constitute an offer or a solicitation to buy or sell any security. Sprott and PillarFour consider this note to be an acceptable minor non-monetary benefit as defined by the FCA which may be received without charge. This is because the content is either considered to be commissioned by Sprott's clients as part of their advisory services to them or is short term market commentary. Neither Sprott nor PillarFour nor any of its directors, officers, employees or agents shall have any liability, howsoever arising, for any error or incompleteness of fact or opinion in it or lack of care in its preparation or publication; provided that this shall not exclude liability to the extent that this is impermissible under the law relating to financial services. All statements and opinions are made as of the date on the face of this document and are not held out as applicable thereafter. This document is intended for distribution only in those jurisdictions where PillarFour is permitted to distribute its research.

## IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Sprott Capital Partners LP ("SCP"), a company authorized to engage in securities activities in Canada. SCP is not a registered broker/dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Sprott Global Resource Investments Ltd. ("SGRIL"), a broker dealer in the United States registered with the Securities Exchange Commission ("SEC"), the Financial Industry Authority ("FINRA"), and a member of the Securities Investor Protection Corporation ("SIPC"). Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SCP.

SGRIL accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. The analyst whose name appears in this research report is not licensed, registered, or qualified as a research analyst with FINRA and may not be an associated person of SGRIL and, therefore, may not be subject to applicable



# **Equity Research**

restrictions under FINRA Rule 2241 regarding communications by a research analyst with a subject company, public appearances by the research analyst, and trading securities held by a research analyst account. To make further inquiries related to this report, United States residents should contact their SGRIL representative.

### **Analyst Certification/Regulation AC**

The analyst and associate certify that the views expressed in this research report accurately reflect their personal views about the subject securities or issuers. In addition, the analyst and associate certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

**Sprott Capital Partners Explanation of Recommendations:** Should SCP issue research with recommendations, the research rating guidelines will be based on the following recommendations:

**BUY:** The stocks total returns are expected to be materially better than the overall market with higher return expectations needed for more risky securities markets

**NEUTRAL**: The stock's total returns are expected to be in line with the overall market

**SELL:** The stocks total returns are expected to be materially lower than the overall market

**TENDER**: The analyst recommends tendering shares to a formal tender offering

**UNDER REVIEW:** The stock will be placed under review when there is a significant material event with further information pending; and/or when the research analyst determines it is necessary to await adequate information that could potentially lead to a re-evaluation of the rating, target price or forecast; and/or when coverage of a particular security is transferred from one analyst to another to give the new analyst time to reconfirm the rating, target price or forecast.

NOT RATED ((N/R): The stock is not currently rated

Re	search Disclosure	Response
1	SCP and its affiliates collectively beneficially owns 1% or more of any class of the issuer's equity securities <sup>1</sup>	YES
2	The analyst or any associate of the analyst responsible for the report or recommendation or any individual directly involved in the preparation of the report holds or is short any of the issuer's securities directly or through derivatives	YES
3	An SCP partner, director, officer or analyst involved in the preparation of a report on the issuer, has during the preceding 12 months provided services to the issuer for remuneration other than normal course investment advisory or trading execution services	NO
4	SCP has provided investment banking services for the issuer during the 12 months preceding the date of issuance of the research report or recommendation	YES
5	Name of any director, officer, employee or agent of SCP who is an officer, director or employee of the issuer, or who serves in an advisory capacity to the issuer	NO
6	SCP is making a market in an equity or equity related security of the issuer	NO
7	The analyst preparing this report received compensation based upon SCP's investment banking revenue for the issuer	NO
8	The analyst has conducted a site visit and has viewed a major facility or operation of the issuer	YES
9	The analyst has been reimbursed for travel expenses for a site visit by the issuer	NO

## **Sprott Capital Partners Equity Research Ratings:**

Summary of Recommendations as of March 2023					
BUY:	52				
HOLD:	1				
SELL:	0				
UNDER REVIEW:	1				
TENDER:	1				
NOT RATED:	0				
TOTAL	55				

<sup>&</sup>lt;sup>1</sup> As at the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month



Page 5